Perceptive Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Perceptive Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-127	Closed	-$5K	–	172
2017 Q1	$5K	Sell	127 -163,128	-100%	-$7.19M	﹤0.01%	155
2016 Q4	$8.18M	Sell	163,255 -3,254	-2%	-$171K	0.58%	43
2016 Q3	$8.74M	Sell	166,509 -2,930	-2%	-$140K	0.56%	44
2016 Q2	$7.01M	Sell	169,439 -284,690	-63%	-$12.4M	0.49%	47
2016 Q1	$18.5M	Buy	454,129 +20,000	+5%	+$687K	1.62%	15
2015 Q4	$18M	Buy	434,129 +150,000	+53%	+$5.03M	1.33%	19
2015 Q3	$4.37M	Buy	284,129 +60,000	+27%	+$1.29M	0.35%	61
2015 Q2	$5.57M	Hold	224,129	–	–	0.34%	62
2015 Q1	$5.12M	Buy	224,129 +68,873	+44%	+$1.74M	0.4%	51
2014 Q4	$4.19M	Buy	155,256 +5,256	+4%	+$90.5K	0.35%	60
2014 Q3	$1.76M	Hold	150,000	–	–	0.18%	73
2014 Q2	$2.33M	Hold	150,000	–	–	0.23%	61
2014 Q1	$2.95M	Buy	150,000 +17,500	+13%	+$297K	0.31%	58
2013 Q4	$2.23M	Buy	+132,500	New	+$1.65M	0.27%	50

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors's FPRX Position: Q2 2017 in Review

Perceptive Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 127 shares — an estimated $5K sold.

Perceptive Advisors first reported a position in FPRX in Q4 2013 and held it in 14 quarters. The position peaked at $18.5M in Q1 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

Perceptive Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Perceptive Advisors sold 127 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $5K.
Perceptive Advisors first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 14 quarters.
Perceptive Advisors's Five Prime Therapeutics, Inc. position peaked at $18.5M in Q1 2016.
123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.